Pfizer plans to tap lucrative weight-loss market with new pill

If the pill is successful it could ease some of the pressure on Pfizer chief executive Albert Bourla, who has struggled to persuade investors that the company’s pipeline of medicines can eventually arrest its post-pandemic decline

It is unclear if Pfizer's Irish operations will have any role in the production of the pill. Picture: Dan Linehan

Pfizer is moving forward with a weight-loss pill as the drugmaker seeks to crack the multibillion-dollar market for obesity medications and mount a comeback from its post-pandemic malaise.

The once-daily treatment, called danuglipron, will progress to a mid-stage study in the second half of this year, Pfizer said, having cleared a scientific hurdle in a small study.